Neuroscience company Cognivue, has reported a 37 percent research participation rate of historically underserved and underrepresented populations in its national Further the Objective and Clinical Understanding of Cognivue Study (FOCUS).
She brings more than 25 years of experience in leading strategic and commercial excellence for several multinational medical device organizations, including Boston Scientific, Smith and Nephew, Sanofi, and Olympus Corporation of America, according to the company's announcement. Prior to joining Cognivue, Parkyn-Michael was vice president of global marketing for private equity-backed Z-Medica.
The approval “paves the way for Cognivue’s technology to be implemented across the healthcare spectrum in Canada, including in audiology, optometry, neurology, retail pharmacy, employee wellness, and general practice,” according to the company's announcement.
